|
Novel Regulation and Targeting of Macrophages Metabolism in Neuroinflammatory Disorders |
5R01AI144004-04 |
|
NIAID |
2022 |
|
Translational approaches to improve understanding and outcome in Tuberculous meningitis |
5R01AI145436-03 |
|
NIAID |
2022 |
|
Contribution of the effector Treg-B-antibody nexus to the regulation of CNS autoimmunity |
5R01AI148711-03 |
|
NIAID |
2022 |
|
Oligodendrocyte extracellular vesicles: a novel therapy for CNS autoimmunity |
5R01AI152251-03 |
|
NIAID |
2022 |
|
ThGM Cells in CNS Autoimmunity |
5R01AI155974-02 |
|
NIAID |
2022 |
|
Role of IL-7R in CNS autoimmunity |
5R01AI156384-02 |
|
NIAID |
2022 |
|
IL-37: a novel regulator of inflammation in CNS autoimmunity |
5R01AI160189-02 |
|
NIAID |
2022 |
|
Discovery of novel smHDAC8 inhibitors for the treatment of schistosomiasis |
5R21AI146512-02 |
|
NIAID |
2022 |
|
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasis |
5R21AI156554-02 |
|
NIAID |
2022 |
|
A Non-Viral Genetic Vaccine for Prevention and Treatment of Multiple Sclerosis |
5R21AI160738-02 |
|
NIAID |
2022 |